Vigabatrin: Phase II started

Catalyst said investigators at the Mount Sinai School of Medicine began an open-label, U.S. Phase I/II trial to evaluate oral CPP-109 twice daily for 8 weeks in about 10 young adults with treatment-refractory Tourette's disorder. Catalyst will provide the compound and funding for the trial. ...